Cancer is history!
"A drug from Amgen designed to block the cancer protein known as KRAS shrank tumors in 37% of patients with advanced lung cancer and delayed tumor progression by just under seven months, according to results from a clinical trial announced Thursday.
The Amgen drug, a pill called sotorasib, is the most important medicine in Amgen’s cancer research pipeline. ..."
Here is a recent Amgen press release regarding this new drug:
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation FDA Granted Breakthrough Therapy Designation for Sotorasib. Sotorasib Application Being Reviewed Under FDA Real-Time Oncology Review (RTOR) Pilot Program
No comments:
Post a Comment